(NMRA) Neumora Therapeutics - Ratings and Ratios
Kappa Antagonist, Agitation Drug, NMDA Modulator, CK1d Inhibitor
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 82.2% |
| Value at Risk 5%th | 121% |
| Relative Tail Risk | -10.26% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.40 |
| Alpha | -106.07 |
| CAGR/Max DD | -0.65 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.681 |
| Beta | 1.329 |
| Beta Downside | 1.629 |
| Drawdowns 3y | |
|---|---|
| Max DD | 96.89% |
| Mean DD | 58.83% |
| Median DD | 50.56% |
Description: NMRA Neumora Therapeutics October 29, 2025
Neumora Therapeutics (NASDAQ: NMRA) is a clinical-stage biopharma focused on oral small-molecule therapies for central-nervous-system (CNS) disorders, including major depressive disorder (MDD), dementia-related agitation, schizophrenia, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and other neurodegenerative conditions. Its lead asset, navacaprant (NMRA-140), is a once-daily kappa-opioid receptor antagonist currently in a pivotal Phase 3 trial for MDD, while NMRA-511 is in Phase 1 for agitation in Alzheimer’s disease.
Beyond the two clinical programs, Neumora maintains a preclinical pipeline targeting high-unmet-need CNS indications: NMRA-NMDA and NMRA-M4R for schizophrenia, NMRA-CK1d for ALS, NMRA-NLRP3 for broader neurodegeneration, and NMRA-GCase for Parkinson’s disease. The global antidepressant market is estimated at ≈ $15 billion in 2024 and growing at a 3–4 % CAGR, providing a sizable revenue runway should navacaprant achieve regulatory approval. As of the latest 10-Q (Q2 2024), the company reported cash and cash equivalents of roughly $45 million, giving it an estimated 12-month operating runway at current burn rates.
Given the historically high attrition rates in CNS drug development (≈ 80 % failure from Phase 1 to approval) and the aging U.S. population driving demand for neuropsychiatric therapies, NMRA’s focus on novel mechanisms could be a differentiator, but investors should monitor Phase 3 readouts and cash-flow sustainability closely. For a deeper dive into NMRA’s valuation metrics and peer comparisons, the ValueRay platform offers a concise, data-driven snapshot worth reviewing.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -1.17 (>2.0%) and ΔFCFTA -65.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -1.17 (>3.0%) and CFO -208.8m > Net Income -236.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (161.8m) change vs 12m ago 1.42% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 0.0%; Δ 0.0pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -326.5 (EBITDA TTM -243.6m / Interest Expense TTM 747.0k) >= 6 (WARN >= 3) |
Altman Z'' -47.08
| (A) 0.85 = (Total Current Assets 177.1m - Total Current Liabilities 25.8m) / Total Assets 177.8m |
| (B) -6.32 = Retained Earnings (Balance) -1.12b / Total Assets 177.8m |
| warn (B) unusual magnitude: -6.32 — check mapping/units |
| (C) -0.92 = EBIT TTM -243.9m / Avg Total Assets 265.2m |
| (D) -24.63 = Book Value of Equity -1.12b / Total Liabilities 45.7m |
| Total Rating: -47.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 49.46
| 1. Piotroski 0.0pt |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.00 |
| 5. Debt/Ebitda 0.53 |
| 7. RoE -113.8% |
| 8. Revenue Trend data missing |
| 9. EPS Trend 43.42% |
What is the price of NMRA shares?
Over the past week, the price has changed by +2.26%, over one month by -16.20%, over three months by -1.09% and over the past year by -82.97%.
Is NMRA a buy, sell or hold?
- Strong Buy: 1
- Buy: 2
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the NMRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.2 | 406.6% |
| Analysts Target Price | 9.2 | 406.6% |
| ValueRay Target Price | 1.4 | -22.1% |
NMRA Fundamental Data Overview December 21, 2025
P/B = 2.2631
Beta = 3.163
Revenue TTM = 0.0 USD
EBIT TTM = -243.9m USD
EBITDA TTM = -243.6m USD
Long Term Debt = 19.6m USD (from longTermDebt, last quarter)
Short Term Debt = 256.0k USD (from shortTermDebt, last quarter)
Debt = 523.0k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -128.5m USD (from netDebt column, last quarter)
Enterprise Value = 126.4m USD (297.4m + Debt 523.0k - CCE 171.5m)
Interest Coverage Ratio = -326.5 (Ebit TTM -243.9m / Interest Expense TTM 747.0k)
FCF Yield = -165.2% (FCF TTM -208.8m / Enterprise Value 126.4m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 5.32m) / Revenue TTM)
Tobins Q-Ratio = 0.71 (Enterprise Value 126.4m / Total Assets 177.8m)
Interest Expense / Debt = 142.8% (Interest Expense 747.0k / Debt 523.0k)
Taxrate = -0.0% (0.0 / -56.8m)
NOPAT = -243.9m (EBIT -243.9m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 6.85 (Total Current Assets 177.1m / Total Current Liabilities 25.8m)
Debt / Equity = 0.00 (Debt 523.0k / totalStockholderEquity, last quarter 132.2m)
Debt / EBITDA = 0.53 (negative EBITDA) (Net Debt -128.5m / EBITDA -243.6m)
Debt / FCF = 0.62 (negative FCF - burning cash) (Net Debt -128.5m / FCF TTM -208.8m)
Total Stockholder Equity = 207.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -132.9% (out of range, set to none)
RoE = -113.8% (Net Income TTM -236.3m / Total Stockholder Equity 207.6m)
RoCE = -107.4% (out of range, set to none) (EBIT -243.9m / Capital Employed (Equity 207.6m + L.T.Debt 19.6m))
RoIC = -112.2% (out of range, set to none) (NOPAT -243.9m / Invested Capital 217.4m)
WACC = 10.89% (E(297.4m)/V(297.9m) * Re(10.91%) + (debt cost/tax rate unavailable))
Discount Rate = 10.91% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 142.7%
Fair Price DCF = unknown (Cash Flow -208.8m)
EPS Correlation: 43.42 | EPS CAGR: -3.63% | SUE: 0.29 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.32 | Chg30d=-0.042 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-1.03 | Chg30d=-0.016 | Revisions Net=-2 | Growth EPS=+28.3% | Growth Revenue=+0.0%
Additional Sources for NMRA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle